Literature DB >> 18174906

Update on the changing epidemiology of Clostridium difficile-associated disease.

Lynne V McFarland1.   

Abstract

In the past, Clostridium difficile-associated disease (CDAD) was thought of mainly as a nosocomial disease associated with the use of broad-spectrum antibiotics, but its epidemiology seems to be changing. Since 2002, outbreaks of severe CDAD associated with increased mortality and reduced effectiveness of treatment with metronidazole have focused attention on this challenging pathogen. A fluoroquinolone-resistant strain of C. difficile (BI/NAP1/027) has been predominantly associated with these outbreaks. Changes in the epidemiology of CDAD include the emergence of new at-risk populations and the increased incidence of the disease. Infection control programs and more effective treatments offer hope that future outbreaks of CDAD can be controlled.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174906     DOI: 10.1038/ncpgasthep1029

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  46 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

3.  Clinical benefit of infectious diseases consultation: a monocentric prospective cohort study.

Authors:  A de La Blanchardière; J Boutemy; P Thibon; J Michon; R Verdon; V Cattoir
Journal:  Infection       Date:  2012-06-22       Impact factor: 3.553

4.  Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients.

Authors:  Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Chris Funston; Karen Savage; Denise Kelly; Motasem A Aldiab; James C McElnay
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

Review 5.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 6.  Shifting the balance: antibiotic effects on host-microbiota mutualism.

Authors:  Benjamin P Willing; Shannon L Russell; B Brett Finlay
Journal:  Nat Rev Microbiol       Date:  2011-02-28       Impact factor: 60.633

7.  Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid.

Authors:  Joseph A Sorg; Abraham L Sonenshein
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

8.  Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein.

Authors:  Christian Hardt; Thomas Berns; Wolfgang Treder; Franz-Ludwig Dumoulin
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

9.  Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds.

Authors:  Andrea Torti; Andrea Lossani; Lida Savi; Federico Focher; George Edward Wright; Neal Curtis Brown; Wei-Chu Xu
Journal:  Curr Enzym Inhib       Date:  2011-10

10.  Clostridium difficile-associated enteric disease after percutaneous endoscopic gastrostomy.

Authors:  Shiro Yokohama; Masaru Aoshima; Toshiyuki Asama; Junya Shindo; Junichi Maruyama
Journal:  J Gastroenterol       Date:  2009-02-13       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.